{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T23:42:58Z","timestamp":1773272578046,"version":"3.50.1"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,7,21]],"date-time":"2021-07-21T00:00:00Z","timestamp":1626825600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,7,21]],"date-time":"2021-07-21T00:00:00Z","timestamp":1626825600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Mucopolysaccharidosis type II (MPS II; Hunter syndrome) is an X-linked multisystem disorder characterized by glycosaminoglycan (GAG) accumulation, caused by a deficiency of iduronate-2-sulfatase (I2S). Enzyme replacement therapy (ERT) with recombinant idursulfase (IDS), the standard of care, was started in the Philippines in 2017. This study reviewed the clinical outcomes in idursulfase-treated and untreated Filipino MPS II patients who were included in the local Lysosomal Storage Disease (LSD) registry of the Institute of Human Genetics-National Institutes of Health (IHG-NIH) from January 1999 to December 2019.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A retrospective audit of records of MPS II patients listed in the registry was done. Qualified patients were divided into two cohorts: idursulfase-treated group (patients on enzyme replacement therapy, ERT, for\u2009\u2265\u20096\u00a0months) and untreated group. Baseline characteristics, including demographic data, biochemical results, neurocognitive classification, respiratory involvement, mortality, and adverse events, were recorded. Height, weight, cardiac pathology, liver and spleen sizes, six-minute walking test (6MWT), joint mobility, were determined at baseline and at year 1 and 2 of follow up.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Forty male patients were included in this review, with only 8 receiving ERT since 2017. The mean age at diagnosis was 6.99\u00a0years (SD 4.15; 0.75\u201320) and mean age at start of ERT was 14.03\u00a0years (SD 7.1; 4\u201321.5), more delayed than previous reports. Eighty percent have early progressive phenotype which was higher than reported average. The early growth pattern differed in our Filipino cohort, but was followed by the expected slowed growth in later years. Improvements in the following endpoints were observed in the treated cohort: height and weight, cardiac disease, liver and spleen sizes, and joint mobility. There were also positive effects on respiratory involvement and mortality rate. Adverse events were consistent with previous reports.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>ERT is generally well tolerated and effective in reducing GAG storage and improving clinical endpoints among our Filipino MPS II patients. In untreated patients, typical disease progression was observed.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13023-021-01875-5","type":"journal-article","created":{"date-parts":[[2021,7,21]],"date-time":"2021-07-21T04:03:14Z","timestamp":1626840194000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["A review of the clinical outcomes in idursulfase-treated and untreated Filipino patients with mucopolysaccharidosis type II: data from the local lysosomal storage disease registry"],"prefix":"10.1186","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0502-3191","authenticated-orcid":false,"given":"Marie Julianne C.","family":"Racoma","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Kristina Karizza B.","family":"Calibag","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cynthia P.","family":"Cordero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mary Ann R.","family":"Abacan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mary Anne D.","family":"Chiong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,7,21]]},"reference":[{"key":"1875_CR1","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1186\/1750-1172-6-72","volume":"6","author":"M Scarpa","year":"2011","unstructured":"Scarpa M, Alm\u00e1ssy Z, Beck M, Bodamer O, Bruce IA, De Meirleir L, Guffon N, Guill\u00e9n-Navarro E, Hensman P, Jones S, Kamin W, Kampmann C, Lampe C, Lavery CA, Teles EL, Link B, Lund AM, Malm G, Pitz S, Rothera M, Stewart C, Tylki-Szyma\u0144ska A, van der Ploeg A, Walker R, Zeman J, Wraith JE. Hunter Syndrome European Expert Council. Mucopolysaccharidosis type II: European recommendations for the diagnosis and multidisciplinary management of a rare disease. Orphanet J Rare Dis. 2011;6:72.","journal-title":"Orphanet J Rare Dis"},{"key":"1875_CR2","first-page":"579","volume-title":"Inborn metabolic diseases: diagnosis and treatment","author":"S Jones","year":"2016","unstructured":"Jones S, Wijburg F. Mucopolysaccharidoses, oligosaccharidoses and sialic acid disorders. In: Saudubray JM, Walter JH, Baumgartner MR, editors. Inborn metabolic diseases: diagnosis and treatment. 6th ed. Berlin: Springer; 2016. p. 579\u201384.","edition":"6"},{"issue":"4","key":"1875_CR3","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1080\/21678707.2017.1296761","volume":"5","author":"M Stapleton","year":"2017","unstructured":"Stapleton M, Kubaski F, Mason R, Yabe H, Suzuki Y, Orii K, et al. Presentation and treatments for Mucopolysaccharidosis Type II (MPS II; Hunter Syndrome). Expert Opin Orphan Drugs. 2017;5(4):295\u2013307.","journal-title":"Expert Opin Orphan Drugs"},{"key":"1875_CR4","first-page":"79","volume":"5","author":"S Sestito","year":"2015","unstructured":"Sestito S, Concolino D, Ceravolo F, Grisolia M, Pascale E, Pensabene L. Profile of idursulfase for the treatment of Hunter syndrome. Res Rep Endocrine Disorders. 2015;5:79\u201390.","journal-title":"Res Rep Endocrine Disorders"},{"key":"1875_CR5","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.ymgme.2019.07.016","volume":"129","author":"A Broomfield","year":"2020","unstructured":"Broomfield A, Davison J, Roberts J, Stewart C, Hensman P, Beesley C, Tylee K, Rust S, Schwahn B, Jameson E, Vijay S, Santra S, Sreekantam S, Ramaswami U, Chakrapani A, Raiman J, Cleary M, Jones S. Ten years of enzyme replacement therapy in paediatric onset mucopolysaccharidosis II in England. Mol Genet Metab. 2020;129:98\u2013105.","journal-title":"Mol Genet Metab"},{"key":"1875_CR6","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1186\/s13023-017-0712-3","volume":"12","author":"J Muenzer","year":"2017","unstructured":"Muenzer J, Giugliani R, Scarpa M, Tylki-Szyma\u0144ska A, Jego V, Beck M. Clinical outcomes in idursulfase-treated patients with mucopolysaccharidosis type II: 3-year data from the hunter outcome survey (HOS). Orphanet J Rare Dis. 2017;12:161.","journal-title":"Orphanet J Rare Dis"},{"key":"1875_CR7","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1007\/s10545-014-9686-7","volume":"37","author":"C Lampe","year":"2014","unstructured":"Lampe C, Bosserhoff A, Burton B, Giugliani R, de Souza C, Bittar C, Muschol N, Olson R, Mendelsohn N. Long-term experience with enzyme replacement therapy (ERT) in MPS II patients with a severe phenotype: an international case series. J Inherit Metab Dis. 2014;37:823\u20139.","journal-title":"J Inherit Metab Dis"},{"issue":"1","key":"1875_CR8","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.ymgme.2009.08.006","volume":"99","author":"T Okuyama","year":"2010","unstructured":"Okuyama T, Tanaka A, Suzuki Y, Ida H, Tanaka T, Cox G, et al. Japan Elaprase\u00ae Treatment (JET) study: Idursulfase enzyme replacement therapy in adult patients with attenuated Hunter syndrome (Mucopolysaccharidosis II, MPS II). Mol Genet Metab. 2010;99(1):18\u201325.","journal-title":"Mol Genet Metab"},{"key":"1875_CR9","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1007\/s10545-017-0075-x","volume":"40","author":"B Burton","year":"2017","unstructured":"Burton B, Jego V, Mikl J, Jones S. Survival in idursulfase-treated and untreated patients with mucopolysaccharidosis type II: data from the Hunter Outcome Survey (HOS). J Inherit Metab Dis. 2017;40:867\u201374.","journal-title":"J Inherit Metab Dis"},{"issue":"3","key":"1875_CR10","doi-asserted-by":"publisher","first-page":"236","DOI":"10.47895\/amp.v54i3.1648","volume":"54","author":"M Faner","year":"2020","unstructured":"Faner M, Chiong MD. Clinical profiles and outcomes of the most common inherited metabolic diseases in the philippines: a review of the national institutes of health\u2014Institute of Human Genetics Metabolic Registry. Acta Med Philipp. 2020;54(3):236\u201343.","journal-title":"Acta Med Philipp"},{"issue":"11","key":"1875_CR11","doi-asserted-by":"crossref","first-page":"804","DOI":"10.47102\/annals-acadmedsg.V35N11p804","volume":"35","author":"I Tan","year":"2006","unstructured":"Tan I, Gajra B, Lim M. Study of inherited metabolic disorders in Singapore\u201413 years experience. Ann Acad Med Singapore. 2006;35(11):804\u201313.","journal-title":"Ann Acad Med Singapore"},{"issue":"2","key":"1875_CR12","doi-asserted-by":"publisher","first-page":"254","DOI":"10.3346\/jkms.2014.29.2.254","volume":"29","author":"S Cho","year":"2014","unstructured":"Cho S, Huh R, Chang M, Lee J, Kwun Y, Maeng S, Kim S, Sohn Y, Park S, Kwon E, Han S, Jung J, Jin D. Impact of enzyme replacement therapy on linear growth in Korean patients with mucopolysaccharidosis type II (hunter syndrome). J Korean Med Sci. 2014;29(2):254.","journal-title":"J Korean Med Sci"},{"key":"1875_CR13","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s13023-016-0558-0","volume":"12","author":"M Chiong","year":"2017","unstructured":"Chiong M, Canson D, Abacan M, Baluyot M, Cordero C, Silao C. Clinical, biochemical and molecular characteristics of Filipino patients with mucopolysaccharidosis type II: hunter syndrome. Orphanet J Rare Dis. 2017;12:7.","journal-title":"Orphanet J Rare Dis"},{"key":"1875_CR14","unstructured":"Abacan MAR, Chiong MAD. Treatment Guidelines for Filipino MPS Patients. (unpublished). 2013"},{"key":"1875_CR15","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.ymgme.2013.03.001","volume":"109","author":"S Jones","year":"2013","unstructured":"Jones S, Parini R, Harmatz P, Giugliani R, Fang J, Mendelsohn N. The effect of idursulfase on growth in patients with Hunter syndrome: Data from the Hunter Outcome Survey (HOS). Mol Genet Metab. 2013;109:41\u20138.","journal-title":"Mol Genet Metab"},{"key":"1875_CR16","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1016\/j.ymgme.2016.01.009","volume":"117","author":"R Parini","year":"2016","unstructured":"Parini R, Jones S, Harmatz P, Giugliani R, Mendelsohn N. The natural history of growth in patients with Hunter syndrome: data from the Hunter Outcome Survey (HOS). Mol Genet Metab. 2016;117:438\u201346.","journal-title":"Mol Genet Metab"},{"key":"1875_CR17","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1186\/s13023-014-0129-1","volume":"9","author":"R Tomanin","year":"2014","unstructured":"Tomanin R, Zanetti A, D\u2019Avanzo F, Rampazzo A, Gasparotto N, Parini R, Pascarella A, Concolino D, Procopio E, Fiumara A, Borgo A, Frigo A, Scarpa M. Clinical efficacy of enzyme replacement therapy in paediatric Hunter patients, an independent study of 3.5 years. Orphanet J Rare Dis. 2014;9:129.","journal-title":"Orphanet J Rare Dis"},{"key":"1875_CR18","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1111\/j.1469-8749.1983.tb13794.x","volume":"25","author":"ID Young","year":"1983","unstructured":"Young ID, Harper PS. The natural history of the severe form of Hunter\u2019s syndrome: a study based on 52 cases. Dev Med Child Neurol. 1983;25:481\u20139.","journal-title":"Dev Med Child Neurol"},{"issue":"2","key":"1875_CR19","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1097\/GIM.0b013e3181fea459","volume":"13","author":"J Muenzer","year":"2010","unstructured":"Muenzer J, Beck M, Eng C, Giugliani R, Harmatz P, Martin R, et al. Long-term, open-labeled extension study of idursulfase in the treatment of Hunter syndrome. Genet Med. 2010;13(2):95\u2013101.","journal-title":"Genet Med"},{"key":"1875_CR20","first-page":"3421","volume-title":"Themetabolic and molecular bases of inherited disease","author":"E Neufeld","year":"2001","unstructured":"Neufeld E, Muenzer J. The mucopolysaccharidoses. In: Schriver CR, Beaudet AL, Sly WS, Valle D, editors. Themetabolic and molecular bases of inherited disease. New York: McGraw-Hill; 2001. p. 3421\u201352."},{"key":"1875_CR21","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1007\/s00431-007-0635-4","volume":"167","author":"J Wraith","year":"2007","unstructured":"Wraith J, Scarpa M, Beck M, Bodamer O, De Meirleir L, Guffon N, Meldgaard Lund A, Malm G, Van der Ploeg A, Zeman J. Mucopolysaccharidosis type II (Hunter syndrome): a clinical review and recommendations for treatment in the era of enzyme replacement therapy. Eur J Pediatr. 2007;167:267\u201377.","journal-title":"Eur J Pediatr"},{"key":"1875_CR22","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1007\/s10545-009-1119-7","volume":"32","author":"S Jones","year":"2009","unstructured":"Jones S, Alm\u00e1ssy Z, Beck M, Burt K, Clarke J, Giugliani R, Hendriksz C, Kroepfl T, Lavery L, Lin S, Malm G, Ramaswami U, Tincheva R, Wraith J. Mortality and cause of death in mucopolysaccharidosis type II\u2014a historical review based on data from the Hunter Outcome Survey (HOS). J Inherit Metab Dis. 2009;32:534\u201343.","journal-title":"J Inherit Metab Dis"},{"issue":"3","key":"1875_CR23","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/j.ymgme.2013.08.002","volume":"110","author":"AJ Barbier","year":"2013","unstructured":"Barbier AJ, Bielefeld B, Whiteman DA, Natarajan M, Pano A, Amato DA. The relationship between anti-idursulfase antibody status and safety and efficacy outcomes in attenuated mucopolysaccharidosis II patients aged 5 years and older treated with intravenous idursulfase. Mol Genet Metab. 2013;110(3):303\u201310.","journal-title":"Mol Genet Metab"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-021-01875-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-021-01875-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-021-01875-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,6]],"date-time":"2023-11-06T03:51:11Z","timestamp":1699242671000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-021-01875-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,21]]},"references-count":23,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["1875"],"URL":"https:\/\/doi.org\/10.1186\/s13023-021-01875-5","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-98874\/v1","asserted-by":"object"}]},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,21]]},"assertion":[{"value":"26 October 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 May 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Waiver of informed consent was applied since the retrospective method of data collection would entail not more than minimal risk. The study protocol was approved by UPM Research Ethics Board (2020-108-01).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"We are reporting that MADC and MARA are co-investigators for LSD Registry Project in the Philippines (Genzyme-Sanofi), and both have participated in the clinical trial SHP-ELA-401 (Shire Human Genetics Therapies).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"323"}}